Evidence map›Paper›PMID 38263404›Full record

ArticleCell discovery2024

Integrated compact regulators of protein activity enable control of signaling pathways and genome-editing in vivo.

Nik Franko, António José da Silva Santinha, Shuai Xue, Haijie Zhao, Ghislaine Charpin-El Hamri, Randall Jeffrey Platt, Ana Palma Teixeira, Martin Fussenegger

Open access · goldAbstract read
In one paragraph

Article in Cell discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Nik FrankoDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.ORCID http://orcid.org/0000-0001-5256-2134
António José da Silva SantinhaDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Shuai XueDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.ORCID http://orcid.org/0000-0002-2521-3833
Haijie ZhaoDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Ghislaine Charpin-El HamriDépartement Génie Biologique, Institut Universitaire de Technologie, Université Claude Bernard Lyon 1, Villeurbanne, Cedex, France.
Randall Jeffrey PlattDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Ana Palma TeixeiraDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.ORCID http://orcid.org/0000-0002-9208-8737
Martin FusseneggerDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland. fussenegger@bsse.ethz.ch.ORCID http://orcid.org/0000-0001-8545-667X
ETH Zurich · CHUniversité Claude Bernard Lyon 1 · FRUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viral proteases and clinically safe inhibitors were employed to build integrated compact regulators of protein activity (iCROP) for post-translational regulation of functional proteins by tunable proteolytic activity. In the absence of inhibitor, the co-localized/fused protease cleaves a target peptide sequence introduced in an exposed loop of the protein of interest, irreversibly fragmenting the protein structure and destroying its functionality. We selected three proteases and demonstrated the versatility of the iCROP framework by validating it to regulate the functional activity of ten different proteins. iCROP switches can be delivered either as mRNA or DNA, and provide rapid actuation kinetics with large induction ratios, while remaining strongly suppressed in the off state without inhibitor. iCROPs for effectors of the NF-κB and NFAT signaling pathways were assembled and confirmed to enable precise activation/inhibition of downstream events in response to protease inhibitors. In lipopolysaccharide-treated mice, iCROP-sr-IκBα suppressed cytokine release ("cytokine storm") by rescuing the activity of IκBα, which suppresses NF-κB signaling. We also constructed compact inducible CRISPR-(d)Cas9 variants and showed that iCROP-Cas9-mediated knockout of the PCSK9 gene in the liver lowered blood LDL-cholesterol levels in mice. iCROP-based protein switches will facilitate protein-level regulation in basic research and translational applications.

Identifiers

PMID38263404
PMCPMC10805712
OpenAlexW4391143020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.